| Donald Hudson Parnell Jr, MD | |
|
303 Medical Center Dr, Batesville, MS 38606-8608 | |
| (662) 712-2220 | |
| (662) 712-2449 |
| Full Name | Donald Hudson Parnell Jr |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 30 Years |
| Location | 303 Medical Center Dr, Batesville, Mississippi |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548259245 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | MD32200 (Tennessee) | Secondary |
| 208600000X | Surgery | MD32200 (Mississippi) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sta Home Health And Hospice | Greenwood, MS | Home health agency |
| Panola Medical Center | Batesville, MS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mississippi Ltac Holdings, Llc | 5395135677 | 6 |
| Panola Physician Group Llc | 2668715624 | 23 |
| Progressive Medical Management Of Batesville Llc | 0345583225 | 33 |
News Archive
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that Roche has disclosed positive top-line results from the first randomized trial assessing trastuzumab emtansine in HER2-positive metastatic breast cancer.
The Food and Drug Administration is warning consumers and pet owners not to use drug products, including homeopathic drug products, made by King Bio Inc., Asheville, N.C., and labeled as Dr. King's, as these products may pose a safety risk to people (especially infants, children, pregnant women and those with compromised immune systems), as well as pets due to high levels of microbial contamination identified at the manufacturing site.
Wyeth Pharmaceuticals has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the ReFacto Antihemophilic Factor (Recombinant) R2 Kit, the first needle-less reconstitution device with a prefilled diluent syringe for hemophilia.
A gene associated with both protection against bacterial infection and excessive blood clotting could offer new insights into treatment strategies for deep-vein thrombosis - the formation of a harmful clot in a deep vein.
Teenagers who can describe their negative emotions in precise and nuanced ways are better protected against depression than their peers who can't.
› Verified 6 days ago
| Entity Name | Panola Physician Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528528874 PECOS PAC ID: 2668715624 Enrollment ID: O20190515002618 |
News Archive
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that Roche has disclosed positive top-line results from the first randomized trial assessing trastuzumab emtansine in HER2-positive metastatic breast cancer.
The Food and Drug Administration is warning consumers and pet owners not to use drug products, including homeopathic drug products, made by King Bio Inc., Asheville, N.C., and labeled as Dr. King's, as these products may pose a safety risk to people (especially infants, children, pregnant women and those with compromised immune systems), as well as pets due to high levels of microbial contamination identified at the manufacturing site.
Wyeth Pharmaceuticals has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the ReFacto Antihemophilic Factor (Recombinant) R2 Kit, the first needle-less reconstitution device with a prefilled diluent syringe for hemophilia.
A gene associated with both protection against bacterial infection and excessive blood clotting could offer new insights into treatment strategies for deep-vein thrombosis - the formation of a harmful clot in a deep vein.
Teenagers who can describe their negative emotions in precise and nuanced ways are better protected against depression than their peers who can't.
› Verified 6 days ago
| Entity Name | Progressive Medical Management Of Batesville Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700349222 PECOS PAC ID: 0345583225 Enrollment ID: O20191114002265 |
News Archive
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that Roche has disclosed positive top-line results from the first randomized trial assessing trastuzumab emtansine in HER2-positive metastatic breast cancer.
The Food and Drug Administration is warning consumers and pet owners not to use drug products, including homeopathic drug products, made by King Bio Inc., Asheville, N.C., and labeled as Dr. King's, as these products may pose a safety risk to people (especially infants, children, pregnant women and those with compromised immune systems), as well as pets due to high levels of microbial contamination identified at the manufacturing site.
Wyeth Pharmaceuticals has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the ReFacto Antihemophilic Factor (Recombinant) R2 Kit, the first needle-less reconstitution device with a prefilled diluent syringe for hemophilia.
A gene associated with both protection against bacterial infection and excessive blood clotting could offer new insights into treatment strategies for deep-vein thrombosis - the formation of a harmful clot in a deep vein.
Teenagers who can describe their negative emotions in precise and nuanced ways are better protected against depression than their peers who can't.
› Verified 6 days ago
| Entity Name | Mississippi Ltac Holdings, Llc |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1144983685 PECOS PAC ID: 5395135677 Enrollment ID: O20220809001499 |
News Archive
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that Roche has disclosed positive top-line results from the first randomized trial assessing trastuzumab emtansine in HER2-positive metastatic breast cancer.
The Food and Drug Administration is warning consumers and pet owners not to use drug products, including homeopathic drug products, made by King Bio Inc., Asheville, N.C., and labeled as Dr. King's, as these products may pose a safety risk to people (especially infants, children, pregnant women and those with compromised immune systems), as well as pets due to high levels of microbial contamination identified at the manufacturing site.
Wyeth Pharmaceuticals has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the ReFacto Antihemophilic Factor (Recombinant) R2 Kit, the first needle-less reconstitution device with a prefilled diluent syringe for hemophilia.
A gene associated with both protection against bacterial infection and excessive blood clotting could offer new insights into treatment strategies for deep-vein thrombosis - the formation of a harmful clot in a deep vein.
Teenagers who can describe their negative emotions in precise and nuanced ways are better protected against depression than their peers who can't.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Donald Hudson Parnell Jr, MD 303 Medical Center Dr, Batesville, MS 38606-8608 Ph: (662) 712-2220 | Donald Hudson Parnell Jr, MD 303 Medical Center Dr, Batesville, MS 38606-8608 Ph: (662) 712-2220 |
News Archive
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that Roche has disclosed positive top-line results from the first randomized trial assessing trastuzumab emtansine in HER2-positive metastatic breast cancer.
The Food and Drug Administration is warning consumers and pet owners not to use drug products, including homeopathic drug products, made by King Bio Inc., Asheville, N.C., and labeled as Dr. King's, as these products may pose a safety risk to people (especially infants, children, pregnant women and those with compromised immune systems), as well as pets due to high levels of microbial contamination identified at the manufacturing site.
Wyeth Pharmaceuticals has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the ReFacto Antihemophilic Factor (Recombinant) R2 Kit, the first needle-less reconstitution device with a prefilled diluent syringe for hemophilia.
A gene associated with both protection against bacterial infection and excessive blood clotting could offer new insights into treatment strategies for deep-vein thrombosis - the formation of a harmful clot in a deep vein.
Teenagers who can describe their negative emotions in precise and nuanced ways are better protected against depression than their peers who can't.
› Verified 6 days ago
Dr. Ramon Rosenkrans, M. D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 303 Medical Center Dr, Batesville, MS 38606 Phone: 662-712-2220 |